Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9355503 | 1.00 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| SCHEMBL9355489 | 1.00 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| SCHEMBL8657397 | 1.00 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| SCHEMBL9351131 | 1.00 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| SCHEMBL9355058 | 1.00 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| SCHEMBL9355150 | 1.00 | CYP1A2 (0.52) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| SCHEMBL6670792 | 0.98 | CYP1A2 (0.53) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| SCHEMBL9311598 | 0.92 | CYP1A2 (0.55) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL27604884 | 0.90 | CYP1A2 (0.53) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 | |
| SCHEMBL8812591 | 0.86 | SOAT1 (0.45) | CYP1A2ALDH1A1ALOX15TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003047-B | Method for preparing nitrile by reacting acetone cyanohydrin with alkyl halide | 哈尔滨理工大学 | 2022-05-06 | — | — | CN | disclosed |
| WO-2018132876-A1 | NOVEL GLYCINE TRANSPORT INHIBITORS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF SYDNEY (AU) | 2018-07-26 | — | — | WO | disclosed |
| US-20150322001-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2015-11-12 | — | — | US | disclosed |
| US-20150322001-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2015-11-12 | — | — | US | disclosed |
| US-8765796-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8552039-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7662771-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1658273-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1658273-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005019184-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | CYP1A2 4367/4885ALDH1A1 4814/4885ALOX15 1620/4885 |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | MC4R, GLP1R, MC3R | CYP1A2 4423/4885ALDH1A1 4799/4885ALOX15 1736/4885 |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | CYP1A2 3880/4885ALDH1A1 4836/4885ALOX15 2089/4885 |
| US-20150322001-A1 | OMEGA-3 ANALOGUES | ELOVL3, PTGER3, FFAR3 | CYP1A2 1949/4885ALDH1A1 1463/4885ALOX15 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.